(Q41538789)

English

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

scientific article published on 16 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Young-Suk Lim

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kwan Soo Byun

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Byung Chul Yoo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

So Young Kwon

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Han Chu Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Yung Sang Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

0 references

publication date

16 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

65

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

852-860

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Management of treatment failure in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Antiviral resistance and hepatitis B therapy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Is hepatitis virus resistance to antiviral drugs a threat?

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308353

21 January 2018

Identifiers

10.1136/GUTJNL-2014-308353

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25596179%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41538789&oldid=1561222737"